Abbott Laboratories ABT
Verdict: Sell. Fair value $116 against a price of $124 on 5 Jan 2026, 7% below the price.
In plain words
The case for: Wide competitive moat provides durability. Market leadership enables pricing power. Industry tailwinds with growing market.
The case against: Intense competitive pressure could compress margins. 2024 Net Income increased 134% ($5.72B to $13.40B) while Revenue only grew 4.6% ($40.11B to.... Operating Cash Flow and Balance Sheet data missing from input, preventing verification of cash....
Main risks
- CRITICAL DATA MISSING: Balance Sheet data (Assets, Equity, Debt) is N/A, preventing ROIC, ROIIC, and Solvency analysis.
- Revenue Stagnation: 3-Year CAGR is negative (-0.9%), reflecting the 'COVID cliff' and difficulty replacing pandemic testing revenue.
- Earnings Quality: 2024 Net Margin (31.9%) is >2x the 2023 level (14.2%) on only 4.6% revenue growth, suggesting massive non-recurring gains rather than organic efficiency.
- 2024 Net Income increased 134% ($5.72B to $13.40B) while Revenue only grew 4.6% ($40.11B to...
- Operating Cash Flow and Balance Sheet data missing from input, preventing verification of cash...
- Intense competitive environment